Re: Continuing outcomes relevant to evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene (multiple letters) [2]

Journal of the National Cancer Institute

Volumn 97, Issue 7, 2005, Pages 542-543

  Yalcin, Bulent ^a   Buyukcelik, Abdullah ^a   Yalcin, Samet ^a   Utkan, Gungor ^a   Doruk, Hatice ^a   Dogan, Mutlu ^a   Altan, Mehmet ^a   Martino, Silvana ^b   Cauley, Jane A ^c   Barrett Connor, Elizabeth ^d   Powles, Trevor J ^e   Mershon, John ^f   Disch, Damon ^f   Secrest, Robert J ^f   Cummings, Steven R ^g  

^a ANKARA UNIVERSITY   (Turkey)

^b Cancer Institute Medical Group   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f ELI LILLY AND COMPANY   (United States)

^g CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AROMATASE; BASIC FIBROBLAST GROWTH FACTOR; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; NAPROXEN; PROSTAGLANDIN E2; RALOXIFENE; ROFECOXIB; VALDECOXIB; VASCULOTROPIN; ENZYME INHIBITOR; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PTGS2 PROTEIN, HUMAN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BONE PAIN; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; DRUG USE; FEMALE; GENE OVEREXPRESSION; HUMAN; LETTER; OUTCOMES RESEARCH; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK REDUCTION; STATISTICAL SIGNIFICANCE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG POTENTIATION; EPIDEMIOLOGY; INCIDENCE; NOTE; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; TREATMENT OUTCOME; UNITED STATES;

BREAST NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); CYCLOOXYGENASE 2; DOUBLE-BLIND METHOD; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; HUMANS; INCIDENCE; MEMBRANE PROTEINS; OSTEOPOROSIS, POSTMENOPAUSAL; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; THROMBOEMBOLISM; TREATMENT OUTCOME; UNITED STATES;

EID: 17844382390     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji090     Document Type: Letter

References (0)